---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-26-000025"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2026-05-20T20:37:01+00:00"
generated_at: "2026-05-20T20:39:30.432671+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Supernus to pay $33.4M CVR milestone payment after Milestone 1 achieved March 18

## Summary
- Milestone 1 under July 2025 CVR Agreement achieved on March 18, 2026; triggers $0.50 per CVR payment.
- Aggregate milestone payment ~$33.4 million, payable in cash within 20 business days of May 17, 2026 Notice Date.
- Company will deposit funds with Rights Agent Equiniti Trust Company for distribution to CVR holders.
- CVRs were issued as part of prior business combination; this payment reduces future contingent liability.

## SEC filing metadata
- accession: 0001356576-26-000025
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2026-05-20T20:37:01+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000025/0001356576-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000025/supn-20260517.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-26-000025
- JSON: https://secwatch.observer/filing/0001356576-26-000025.json
- Plain text: https://secwatch.observer/filing/0001356576-26-000025.txt

## Key facts
- Debt Financings
  SUPERNUS PHARMACEUTICALS, INC. incurred debt of approximately $33.4 million with Equiniti Trust Company, LLC.
  - Principal: approximately $33.4 million
  - Counterparty: Equiniti Trust Company, LLC
  - Event: incurrence
  source text: On May 17, 2026 (the “Notice Date”), pursuant to the Contingent Value Right Agreement (the “CVR Agreement”) entered into as of July 30, 2025, by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent, the Company notified the Rights Agent that Milestone 1, as defined in the CVR Agreement, was achieved on March 18, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000025/0001356576-26-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.